Niacin therapy improves outcome and normalizes metabolic abnormalities in an NAXD-deficient patient
Brain
.
2022 Jun 3;145(5):e36-e40.
doi: 10.1093/brain/awac065.
Authors
Joshua Manor
1
2
,
Daniel G Calame
1
2
3
,
Charul Gijavanekar
1
,
Alyssa Tran
1
2
,
Jawid M Fatih
1
,
Seema R Lalani
1
2
,
Elizabeth Mizerik
1
2
,
Mered Parnes
2
3
,
Vidya P Mehta
4
,
Adekunle M Adesina
4
,
James R Lupski
1
2
5
6
,
Fernando Scaglia
1
2
7
,
Sarah H Elsea
1
Affiliations
1
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
2
Texas Children's Hospital, Houston, TX, USA.
3
Division of Pediatric Neurology and Developmental Neuroscience, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
4
Department of Pathology, Texas Children's Hospital, Houston, TX, USA.
5
Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA.
6
Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
7
Joint BCM-CUHK Center of Medical Genetics, Prince of Wales Hospital, Sha Tin, Hong Kong SAR.
PMID:
35231119
DOI:
10.1093/brain/awac065
No abstract available
Publication types
Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Cholesterol, HDL
Humans
Niacin* / therapeutic use
Substances
Cholesterol, HDL
Niacin
Grants and funding
U54 HG006542/HG/NHGRI NIH HHS/United States
UM1 HG006542/HG/NHGRI NIH HHS/United States
R35 NS105078/NS/NINDS NIH HHS/United States
R01 CA211176/CA/NCI NIH HHS/United States
T32 NS043124/NS/NINDS NIH HHS/United States